Company / Operating Income
Fulgent Genetics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$91.1M
FY2025
5-year range
-$91.1M / $676.0M
FY2021-FY2025
Trend
-23.2%
vs FY2024
Sector context
#131 of 156
Health Care
What the data says
Fulgent Genetics, Inc.'s operating income of -$91M is lower than 84% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from -$91M in FY2025 to $676M in FY2023.
Based on SEC 10-K filings.
-$91M in FY2025.
Declined from $676M to -$91M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 156This company -$91.1M Sector average $733.1M
▼
-112.4% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 23.2% year-over-year.
- Ranks #131 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$91.1M | -23.2% |
| FY2024 | -$73.9M | -110.9% |
| FY2023 | $676.0M | +133.0% |
| FY2022 | $290.2M | +67893.9% |
| FY2021 | -$428.0K | -100.1% |
| FY2020 | $290.2M | +5823.0% |
| FY2019 | -$5.1M | -45.6% |
| FY2018 | -$3.5M | +0.0% |
| FY2017 | -$3.5M | -251.7% |
| FY2016 | -$990.0K | +80.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026